Takara Bio enters into a license agreement of RetroNectin with Fondazione Telethon ETS

Kusatsu/Shiga, Japan—September 25, 2023—Takara Bio Inc. announces that it has entered into a License Agreement with non-profit/charity organization, Fondazione Telethon ETS (“Telethon”) (https://www.telethon.it/en), Italy, under which Takara Bio grants Telethon a commercial license to use RetroNectin. Under this agreement, Takara Bio provides Telethon with reliable supplies of RetroNectin.

The technologies licensed to Telethon are based on Takara Bio’s proprietary RetroNectin method, which includes a technology enabling highly efficient gene transduction to cells by retrovirus/lentivirus vector and expansion of T-cells with high efficiency. With such advantages, RetroNectin method is one of the mostly used standard protocols utilized for “Engineered Gene Therapy”, which includes promising TCR and CAR gene therapies recently raising higher expectations, as well as “Hematopoietic stem cell Gene Therapy”.

Under the agreement signed with Takara Bio, Telethon is allowed to use RetroNectin for production of its cell & gene therapy products, one of which is Strimvelis, a rare disease treatment targeting Adenosine deaminase deficiency.

Takara Bio is promoting supply of RetroNectin to clinical development of engineered gene and cell therapy actively pursued worldwide in recent years, and expects higher sales growth in the future.

Corporate Department, Takara Bio Inc.
E-mail: bio-ir@takara-bio.co.jp

Forward-looking statements

Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and product strategies, decline in selling power of the Company’s existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.